Lidwien P. Smabers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lidwien P. Smabers has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jeanine M. L. Roodhart
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
10 shared publications - Edwin Cuppen
Hartwig Medical Foundation, Amsterdam, The Netherlands
9 shared publications - Liselot B. J. Valkenburg-Van Iersel
Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center , Maastricht, 6229 HX
9 shared publications - Maarten A. Huismans
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
9 shared publications - Miriam Koopman
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
9 shared publications - Onno Kranenburg
Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
9 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Baseline characteristics of the study population, with key demographic, clinical, and molecular details from regular diagnostic sequencing.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Baseline characteristics of the study population, with key demographic, clinical, and molecular details from regular diagnostic sequencing.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom, somatic driver mutations. MS, microsatellite status; MSI, microsatellite instability; MSS, microsatellite stability; Seq, sequencing; TML, tumor mutational load.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom, somatic driver mutations. MS, microsatellite status; MSI, microsatellite instability; MSS, microsatellite stability; Seq, sequencing; TML, tumor mutational load.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Tables S1-S6 and Figures S1–S8
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Tables S1-S6 and Figures S1–S8
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Clinical variables related to PDO establishment success: CEA, LDH, mutational status, sex, primary tumor sidedness, prior chemotherapeutic treatment, metastatic site of the biopsy, WGS success, and aggregated biopsy color (brown, pink, red, and white). CEA, carcinoembryonic antigen; mut, mutant.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Clinical variables related to PDO establishment success: CEA, LDH, mutational status, sex, primary tumor sidedness, prior chemotherapeutic treatment, metastatic site of the biopsy, WGS success, and aggregated biopsy color (brown, pink, red, and white). CEA, carcinoembryonic antigen; mut, mutant.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
A, Heatmap of the drug sensitivity per PDO for different types of systemic treatment. The columns show the normalized GRAUC (left) and AUC (right), respectively. Potential other treatment options for intermediate or high 5-FU and oxaliplatin–resistant PDOs, as well as intermediate or high 5-FU and oxaliplatin–sensitive but 5-FU and irinotecan–resistant PDOs, are shown in black bars. PDOs that were not screened are shown in gray. B, Sensitivity (GRAUC) to doublet and triplet chemotherapy showing increased sensitivity with the addition of irinotecan. C, Sensitivity (normalized GRAUC) to panitumumab for PDOs categorized according to the tumor’s mutational status and primary tumor sidedness (RAS-mutant, BRAF-mutant, and/or right-sided; RAS/BRAF-WT and left-sided. Boxplots show the minimum, median, maximum, upper and lower quartiles, and individual data points. iri, irinotecan; oxa, oxaliplatin; TT, trifluridine/tipiracil.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
A, Heatmap of the drug sensitivity per PDO for different types of systemic treatment. The columns show the normalized GRAUC (left) and AUC (right), respectively. Potential other treatment options for intermediate or high 5-FU and oxaliplatin–resistant PDOs, as well as intermediate or high 5-FU and oxaliplatin–sensitive but 5-FU and irinotecan–resistant PDOs, are shown in black bars. PDOs that were not screened are shown in gray. B, Sensitivity (GRAUC) to doublet and triplet chemotherapy showing increased sensitivity with the addition of irinotecan. C, Sensitivity (normalized GRAUC) to panitumumab for PDOs categorized according to the tumor’s mutational status and primary tumor sidedness (RAS-mutant, BRAF-mutant, and/or right-sided; RAS/BRAF-WT and left-sided. Boxplots show the minimum, median, maximum, upper and lower quartiles, and individual data points. iri, irinotecan; oxa, oxaliplatin; TT, trifluridine/tipiracil.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Correlations between patient response (best RECIST response, size change of all target lesions, and the biopsied lesion) and PDO response (normalized GRAUC per treatment in A–C and AUC in D–F). ROC curves showing the performance of the PDO classification based on GRAUC. The curve plots the true-positive rate (sensitivity) against the false-positive rate (1 − specificity). The AUC indicates the model’s ability to distinguish between responders and nonresponders to 5-FU and oxaliplatin, defined by size change of all target lesions (G) and the biopsied lesion (H). Kaplan–Meier PFS (I) and OS (J) curves of patients stratified by PDO sensitivity to 5-FU and oxaliplatin, based on normalized GRAUC (cutoff = 0.63). Censored events are indicated by vertical bars on the corresponding curve. The table underneath each plot denotes the numbers at risk. Log-rank test–based P value is shown. SN-38, active metabolite of irinotecan.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Correlations between patient response (best RECIST response, size change of all target lesions, and the biopsied lesion) and PDO response (normalized GRAUC per treatment in A–C and AUC in D–F). ROC curves showing the performance of the PDO classification based on GRAUC. The curve plots the true-positive rate (sensitivity) against the false-positive rate (1 − specificity). The AUC indicates the model’s ability to distinguish between responders and nonresponders to 5-FU and oxaliplatin, defined by size change of all target lesions (G) and the biopsied lesion (H). Kaplan–Meier PFS (I) and OS (J) curves of patients stratified by PDO sensitivity to 5-FU and oxaliplatin, based on normalized GRAUC (cutoff = 0.63). Censored events are indicated by vertical bars on the corresponding curve. The table underneath each plot denotes the numbers at risk. Log-rank test–based P value is shown. SN-38, active metabolite of irinotecan.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Schematic overview of the study. Patients underwent a biopsy of a metastasis for PDO culture and WGS, before starting a new line of systemic treatment. Predictors of successful PDO establishment were identified: male sex, increased LDH, biopsy in academic hospitals, optimized culture conditions, and experience. A total of 42 PDOs were screened for standard-of-care treatments, and the patient received standard systemic treatment. PDO response was correlated with patient response, and the association between PDO response and survival was assessed. (Created in BioRender. Roodhart, J. [2025] https://BioRender.com/by1f1uq.)
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Schematic overview of the study. Patients underwent a biopsy of a metastasis for PDO culture and WGS, before starting a new line of systemic treatment. Predictors of successful PDO establishment were identified: male sex, increased LDH, biopsy in academic hospitals, optimized culture conditions, and experience. A total of 42 PDOs were screened for standard-of-care treatments, and the patient received standard systemic treatment. PDO response was correlated with patient response, and the association between PDO response and survival was assessed. (Created in BioRender. Roodhart, J. [2025] https://BioRender.com/by1f1uq.)
- 7 November 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (48) , 4686-4698
Clinical implications of whole genome sequencing in metastatic colorectal cancer
Whole genome sequencing (WGS) provides complete genetic information in one test, supporting the shift towards individualized metastatic colorectal cancer (mCRC) treatment. Although WGS is validated as a diagnostic test, the potential clinical implications for mCRC remain unknown. We evaluated the clinical consequences of WGS in 96 mCRC patients. Clinically actionable biomarkers were identified by a molecular biologist and medical oncologist, with added value defined as biomarkers undetected by standard diagnostics. We evaluated how these biomarkers informed treatment decisions. We used patient-derived organoids (PDOs) to test drug sensitivity to MET, MEK, and CDK4/6 inhibitors, translating genomic findings into functional evidence. WGS yields biomarkers with clinical implications in 81% of patients, with 49% (N = 47/96) identified by WGS that were not detected by guideline-based diagnostics, and 40% (N = 38/96) not detected by applied diagnostics. The proportion of patients receiving biomarker-based treatment has increased from 11% to at least 24% by WGS. PDOs with actionable biomarkers showed clear differential response to different biomarker-based treatments. WGS enables considerably more personalized therapeutic interventions and represents a promising approach in advancing precision oncology for mCRC patients. PDO pre-screening can refine therapy by identifying (in)effective treatments in a patient-specific context, to accelerate the development of personalized treatment.
- 7 November 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (48) , 4686-4698
Clinical implications of whole genome sequencing in metastatic colorectal cancer
Whole genome sequencing (WGS) provides complete genetic information in one test, supporting the shift towards individualized metastatic colorectal cancer (mCRC) treatment. Although WGS is validated as a diagnostic test, the potential clinical implications for mCRC remain unknown. We evaluated the clinical consequences of WGS in 96 mCRC patients. Clinically actionable biomarkers were identified by a molecular biologist and medical oncologist, with added value defined as biomarkers undetected by standard diagnostics. We evaluated how these biomarkers informed treatment decisions. We used patient-derived organoids (PDOs) to test drug sensitivity to MET, MEK, and CDK4/6 inhibitors, translating genomic findings into functional evidence. WGS yields biomarkers with clinical implications in 81% of patients, with 49% (N = 47/96) identified by WGS that were not detected by guideline-based diagnostics, and 40% (N = 38/96) not detected by applied diagnostics. The proportion of patients receiving biomarker-based treatment has increased from 11% to at least 24% by WGS. PDOs with actionable biomarkers showed clear differential response to different biomarker-based treatments. WGS enables considerably more personalized therapeutic interventions and represents a promising approach in advancing precision oncology for mCRC patients. PDO pre-screening can refine therapy by identifying (in)effective treatments in a patient-specific context, to accelerate the development of personalized treatment.
- Open Access
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5015-5026
Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Purpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value. Experimental Design: Patients with mCRC underwent a metastatic biopsy for PDO establishment, before starting new systemic treatment. Predictors of PDO establishment were identified. PDOs were incubated with a seven-drug panel, including the patient’s treatment, to determine drug sensitivity as measured by CyQUANT cell viability [area under the nonfitted “curve” of the raw viability or growth rate inhibition values (AUC and GRAUC) and concentration that gives half-maximal viability or GR inhibition (IC50 and GR50)]. Patient response was measured by size change of biopsied and all target lesions. The diagnostic performance was evaluated by positive predictive value, negative predictive value, and area under the ROC curve. Additionally, the association between PDO response and survival was assessed. Results: A total of 232 patients were included, and 205 biopsies were obtained. PDO establishment success increased from 22% to 75%, yielding 52% overall. Male sex, increased lactate dehydrogenase, biopsy in academic hospitals, optimized culture conditions, and experience were related to PDO establishment success. In this interim analysis, focused on oxaliplatin-based doublet chemotherapy, 42 PDOs were screened. PDO drug sensitivity significantly correlated with the response of the biopsied lesion (R = 0.41–0.49, P < 0.011) and all target lesions (R = 0.54–0.60, P < 0.001) for all treatments combined. The 5-fluorouracil and oxaliplatin PDO screens demonstrated high predictive accuracy (positive predictive value: 0.78; negative predictive value: 0.80; area under the ROC curve: 0.78–0.88) and were associated with progression-free survival and overall survival (P = 0.016 and 0.049). Conclusions: We identified predictors for successful mCRC PDO establishment and validated that PDOs can accurately predict patient outcomes during systemic treatment, specifically with 5-fluorouracil and oxaliplatin.
- 22 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 5015-5026
Open AccessPatient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Purpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value. Experimental Design: Patients with mCRC underwent a metastatic biopsy for PDO establishment, before starting new systemic treatment. Predictors of PDO establishment were identified. PDOs were incubated with a seven-drug panel, including the patient’s treatment, to determine drug sensitivity as measured by CyQUANT cell viability [area under the nonfitted “curve” of the raw viability or growth rate inhibition values (AUC and GRAUC) and concentration that gives half-maximal viability or GR inhibition (IC50 and GR50)]. Patient response was measured by size change of biopsied and all target lesions. The diagnostic performance was evaluated by positive predictive value, negative predictive value, and area under the ROC curve. Additionally, the association between PDO response and survival was assessed. Results: A total of 232 patients were included, and 205 biopsies were obtained. PDO establishment success increased from 22% to 75%, yielding 52% overall. Male sex, increased lactate dehydrogenase, biopsy in academic hospitals, optimized culture conditions, and experience were related to PDO establishment success. In this interim analysis, focused on oxaliplatin-based doublet chemotherapy, 42 PDOs were screened. PDO drug sensitivity significantly correlated with the response of the biopsied lesion (R = 0.41–0.49, P < 0.011) and all target lesions (R = 0.54–0.60, P < 0.001) for all treatments combined. The 5-fluorouracil and oxaliplatin PDO screens demonstrated high predictive accuracy (positive predictive value: 0.78; negative predictive value: 0.80; area under the ROC curve: 0.78–0.88) and were associated with progression-free survival and overall survival (P = 0.016 and 0.049). Conclusions: We identified predictors for successful mCRC PDO establishment and validated that PDOs can accurately predict patient outcomes during systemic treatment, specifically with 5-fluorouracil and oxaliplatin.
- Top Cited Papers
- 17 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6697) , 785-792
DNA damage induces p53-independent apoptosis through ribosome stalling
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown. We observed that p53-independent apoptosis in response to DNA damage coincided with translation inhibition, which was characterized by ribosome stalling on rare leucine-encoding UUA codons and globally curtailed translation initiation. A genetic screen identified the transfer RNAse SLFN11 and the kinase GCN2 as factors required for UUA stalling and global translation inhibition, respectively. Stalled ribosomes activated a ribotoxic stress signal conveyed by the ribosome sensor ZAKα to the apoptosis machinery. These results provide an explanation for the frequent inactivation of SLFN11 in chemotherapy-unresponsive tumors and highlight ribosome stalling as a signaling event affecting cell fate in response to DNA damage.
- 17 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6697) , 785-792
Top Cited PapersDNA damage induces p53-independent apoptosis through ribosome stalling
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown. We observed that p53-independent apoptosis in response to DNA damage coincided with translation inhibition, which was characterized by ribosome stalling on rare leucine-encoding UUA codons and globally curtailed translation initiation. A genetic screen identified the transfer RNAse SLFN11 and the kinase GCN2 as factors required for UUA stalling and global translation inhibition, respectively. Stalled ribosomes activated a ribotoxic stress signal conveyed by the ribosome sensor ZAKα to the apoptosis machinery. These results provide an explanation for the frequent inactivation of SLFN11 in chemotherapy-unresponsive tumors and highlight ribosome stalling as a signaling event affecting cell fate in response to DNA damage.